SEH1L and prostate adenocarcinoma: High expression of SEH1L was associated with poor OS in adrenocortical carcinoma (ACC), KICH, brain lower grade glioma (LGG), LIHC, mesothelioma (MESO), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD) and sarcomav (SARC) (Fig. 2A).